These companies could crush the broader markets this year.
News & Analysis: Acceleron Pharma
Acceleron's shares skyrocketed last month after its experimental PAH drug hit the mark in a midstage trial.
The stock's price surged following a clinical trial success, but should investors now temper their enthusiasm?
A successful midstage clinical trial has investors giddy, but the devil will be in the details.
The new drug treats high blood pressure in the lungs.
Investors breathed a sign of relief as multiple pipeline assets from Celgene closed the year with positive updates.
XLRN earnings call for the period ending .
The biotech's Q3 results and future fortunes hinge on approvals for the blood-disease drug it licensed to Celgene.
The biotech’s pipeline is shrinking, but investors should focus on what will drive near-term value.
The small pharma company had disappointing results from its second phase clinical trials. Here’s why it’s too soon to throw in the towel.